Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
BMJ Case Rep ; 17(5)2024 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-38719261

RESUMEN

Olmesartan is an angiotensin II receptor blocker licensed for the treatment of hypertension. It can cause a sprue-like enteropathy (SLE), characterised by chronic diarrhoea, weight loss and villous atrophy. Transiently raised anti-tissue transglutaminase (ATTG) antibody has also been rarely reported in the literature.We describe the case of a woman in her mid-50s, who presented with a history of intermittent loose stools over 1 year, associated with significant weight loss. She had two marginally raised serum ATTG antibody tests during her work-up.After extensive investigations, she was diagnosed with olmesartan-induced enteropathy. On subsequent follow-up, her symptoms had resolved with cessation of her olmesartan therapy.This case adds to existing literature, highlighting the importance of considering olmesartan as a possible differential diagnosis for SLE. It also reports the presence of a raised ATTG antibody which is infrequently reported in this context.


Asunto(s)
Diarrea , Imidazoles , Tetrazoles , Transglutaminasas , Pérdida de Peso , Humanos , Femenino , Imidazoles/efectos adversos , Diarrea/inducido químicamente , Tetrazoles/efectos adversos , Persona de Mediana Edad , Transglutaminasas/inmunología , Diagnóstico Diferencial , Bloqueadores del Receptor Tipo 1 de Angiotensina II/efectos adversos , Autoanticuerpos/sangre , Proteína Glutamina Gamma Glutamiltransferasa 2 , Enfermedad Crónica , Enfermedad Celíaca/diagnóstico , Proteínas de Unión al GTP/inmunología , Proteínas de Unión al GTP/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA